title: [Sustained weight reduction after cessation of obesity treatment with Sibutramine].
abstract: OBJECTIVE
  Aim of the study was to examine the course of body weight and cardiovascular risk parameters under the everyday life conditions in general practice after obese patients had terminated their sibutramine treatment.
  
  
  METHODS
  Patients were administered sibutramine (10 mg oder 15 mg, once daily) for at least six months could be included in the post-marketing surveillance (PMS) study. Control visits to document body weight, laboratory parameters and blood pressure took place after 12 weeks and after 24 weeks.
  
  
  RESULTS
  In all, 374 patients (77 % women, 20 % men) with an average age of 45.8 +/- 11.8 years terminated the previous sibutramine therapy at the latest with inclusion into the study. On average, they had administered sibutramine for six months. At the end of the 24-week observation period the majority of the patients stated that they had continuously adhered to changed life habits during the last six months. On average, the body weight of the patients did not increase (mean weight reduction of 1 kg between start and end of the observation period). The stable course of the body weight was mirrored by the values of the laboratory parameters: values for total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, serum glucose (fasting), HbA (1c), urea, uric acid and liver parameters remained unchanged compared to the values on entry into the study. Throughout the observation period, blood pressure values remained stable as well.
  
  
  CONCLUSIONS
  Values for body weight, vital signs (blood pressure, heart rate), serum glucose and serum lipids remain constant even after termination of the sibutramine therapy. Possibly, the positive effect on body weight reduction by the treatment with sibutramine support the adherence to a changed life style. Obviously, this action continues after termination of the drug treatment.
authors.affiliation: Teutoburger-Wald-Klinik, Bad Rothenfelde. Alfred.Wirth@lva-hannover.de
authors.forename: A
authors.initials: A
authors.lastname: Wirth
mesh_terms: D001067:Appetite Depressants / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure; D001835:Body Weight; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D003503:Cyclobutanes / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008019:Life Style; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy*; D011358:Product Surveillance, Postmarketing; D012307:Risk Factors
chemical_list: D001067:Appetite Depressants; D001786:Blood Glucose; D003503:Cyclobutanes; D008055:Lipids; C058254:sibutramine